{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-25-003237","form_type":"8-K","ticker":"PHIO","cik":"0001533040","company_name":"Phio Pharmaceuticals Corp.","filed_at":"2025-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.654506+00:00","generated_at":"2026-05-22T07:55:18.061305+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Phio Pharmaceuticals reports complete pathologic response in 2 of 3 patients in third cohort of INTASYL PH-762 trial","bullets":["2 of 3 cSCC patients in Cohort 3 achieved 100% tumor clearance; third patient had <50% clearance.","Across 10 patients in Cohorts 1-3: 4 complete responses, 1 near complete (>90%), 1 partial (>50%).","No dose-limiting toxicities or clinically relevant adverse effects reported; PH-762 well tolerated.","Fourth cohort enrolling; Phio expects to complete trial enrollment in Q3 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-25-003237","json":"https://secwatch.observer/filing/0001683168-25-003237.json","markdown":"https://secwatch.observer/filing/0001683168-25-003237.md","text":"https://secwatch.observer/filing/0001683168-25-003237.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533040/000168316825003237/0001683168-25-003237-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533040/000168316825003237/phio_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T07:55:18.061305+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}